A

AcelRx Pharmaceuticals Inc
F:R5X

Watchlist Manager
AcelRx Pharmaceuticals Inc
F:R5X
Watchlist
Price: 2.106 EUR 9.74% Market Closed
Market Cap: €310.3m

Net Margin

-5 021.7%
Current
Declining
by 6 697.4%
vs 3-y average of 1 675.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-5 021.7%
=
Net Income
$-26.5m
/
Revenue
$620k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-5 021.7%
=
Net Income
€-26.5m
/
Revenue
$620k

Peer Comparison

Country Company Market Cap Net
Margin
US
AcelRx Pharmaceuticals Inc
F:R5X
310.3m EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 15 072 companies
5th percentile
-5 021.7%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

AcelRx Pharmaceuticals Inc
Glance View

Market Cap
310.3m EUR
Industry
Pharmaceuticals

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in Hayward, California and currently employs 43 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Its sufentanil sublingual products include DSUVIA, DZUVEO and Zalviso, which are focused on the treatment of moderate-to-severe acute pain in a medically supervised setting. Its pre-filled syringe product candidates include Ephedrine and Phenylephrine. Its nafamostat mesylate product candidates include Niyad, which is a regional anticoagulant for injection into the extracorporeal circuit, and LTX-608, which is a nafamostat formulation for antiviral treatment of COVID, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), and acute pancreatitis.

R5X Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-5 021.7%
=
Net Income
$-26.5m
/
Revenue
$620k
What is AcelRx Pharmaceuticals Inc's current Net Margin?

The current Net Margin for AcelRx Pharmaceuticals Inc is -5 021.7%, which is below its 3-year median of 1 675.7%.

How has Net Margin changed over time?

Over the last 3 years, AcelRx Pharmaceuticals Inc’s Net Margin has decreased from -1 042.5% to -5 021.7%. During this period, it reached a low of -6 997.7% on Jun 30, 2023 and a high of 15 656.5% on Mar 31, 2023.

Back to Top